Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone ...

For patients with mCRPC with bone metastases, the addition of radium-223 to enzalutamide therapy is associated with improved overall survival.

Patients treated with Xofigo-Xtandi experienced a 5.6-month boost to median OS over those treated with Xtandi alone.

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

The former president announced last year he has an aggressive form of prostate cancer. He and his aides say he’s doing well ...

Research team at OncoRay identifies MMP11 as a promising biomarker for liquid biopsy in prostate cancer Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In ...

While some of his allies have lamented that Biden's legacy as president has been reduced to questions of his declining health and mental acuity, many Democrats are still bitter about Biden's 2024 ...

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to postoperative radiotherapy may provide little survival benefit for most men ...

Final overall survival data for PEACE-3 (NCT02194842) evaluating the combination of enzalutamide (Xtandi) and radium-223 ...

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced that ...